CLINICAL TRIALS PROFILE FOR INVEGA SUSTENNA
✉ Email this page to a colleague
All Clinical Trials for invega sustenna
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | Duke University | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | University of North Carolina, Chapel Hill | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | New York State Psychiatric Institute | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01193153 ↗ | A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder | Completed | Janssen Scientific Affairs, LLC | Phase 3 | 2010-09-01 | This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder. |
| NCT01211704 ↗ | Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism | Withdrawn | Ortho-McNeil, Inc. | Phase 4 | 2010-10-01 | The primary specific aim is to examine the efficacy of Paliperidone extended release Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. The investigators hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) treated group will have a statistically significant advantage on improvement in manic symptoms. They will also have higher rate of treatment response and remission. |
| NCT01211704 ↗ | Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism | Withdrawn | University of Miami | Phase 4 | 2010-10-01 | The primary specific aim is to examine the efficacy of Paliperidone extended release Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. The investigators hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) treated group will have a statistically significant advantage on improvement in manic symptoms. They will also have higher rate of treatment response and remission. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for invega sustenna
Condition Name
Clinical Trial Locations for invega sustenna
Trials by Country
Clinical Trial Progress for invega sustenna
Clinical Trial Phase
Clinical Trial Sponsors for invega sustenna
Sponsor Name
